TG Therapeutics, Inc. stock is surging due to strong financial performance and a promising outlook, driven by the success of its flagship drug, Briumvi. Revenue for Q4 reached $107.3 million, up 146% year-over-year with 2024 total revenue at $313.7 million, largely from Briumvi sales. The company achieved a net income of $23.3 million in Q4, a significant turnaround from a net loss in the previous year, with positive cash flow.